The Journal of clinical psychiatry · 1984
The role of the National Institute on Drug Abuse in the development of naltrexone.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ginzburg H M, Glass W J
Аннотация
Naltrexone was administered to 114 opiate-addicted business executives and 15 opiate-addicted physicians within a highly structured abstinence-oriented aftercare program following an inpatient detoxification program that used clonidine. The majority of patients successfully completed 6 months of naltrexone treatment without missed visits or drug-positive urines, and were still opiate-free at 12- to 18-months follow-up. The most successful outcomes were achieved by those who had entered treatment with unequivocal job jeopardy. Our findings suggest that naltrexone can be an extremely useful adjunct in the treatment of opiate addiction when administered to employed, motivated patients within a highly structured therapeutic program.
Предметные рубрики MeSH
AftercareAnimalsCarcinogensClinical Trials as TopicClonidineDrug Administration ScheduleDrug EvaluationDrug Evaluation, PreclinicalDrug and Narcotic ControlFemaleHumansMaleMiceMotivationNaloxoneNaltrexoneOpioid-Related DisordersPatient ComplianceRatsUnited StatesUnited States Substance Abuse and Mental Health Services Administration